A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine

Antiviral Therapy

Volumn 17, Issue 8, 2012, Pages 1521-1531

  Phanuphak, Nittaya ^a,b   Ananworanich, Jintanat ^a,b,c,d,e   Teeratakulpisarn, Nipat ^b   Jadwattanakul, Tanate ^f   Kerr, Stephen J ^e,g   Chomchey, Nitiya ^a   Hongchookiat, Piranun ^b   Mathajittiphun, Pornpen ^f   Pinyakorn, Suteeraporn ^a,b,e   Rungrojrat, Patcharawee ^a   Praihirunyakit, Pairoa ^a   Gerschenson, Mariana ^c   Phanuphak, Praphan ^a,b,d,e   Valcour, Victor ^a,h   Kim, Jerome H ^a,i   Shikuma, Cecilia ^a,c  

^a South East Asia Research Collaboration with Hawaii ^*  (Thailand)

^b THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^c UNIVERSITY OF HAWAII   (United States)

^d CHULALONGKORN UNIVERSITY   (Thailand)

^e THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^f Queen Savang Vadhana Memorial Hospital   (Thailand)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ US Military HIV Research Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HEMOGLOBIN; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NERAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; VIRUS RNA; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PARESTHESIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THAILAND;

ADENINE; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DIET; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBINS; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; NEVIRAPINE; ORGANOPHOSPHONATES; PERIPHERAL NERVOUS SYSTEM DISEASES; STAVUDINE; TREATMENT OUTCOME; VIRAL LOAD; ZIDOVUDINE;

EID: 84871895043     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2497     Document Type: Article

References (23)

1. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach - 2010 revision. (Accessed 26 December 2011.) Available from http://whqlibdoc.who.int/ publications/2010/9789241599764-eng.pdf
2. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach - 2006 revision. (Accessed 26 December 2011.) Available from http://www.who.int/hiv/ pub/guidelines/artadultguidelines.pdf
3. Gilks CF, Crowley S, Ekpini R, et al. The WHO publichealth approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-510. (Pubitemid 44142772)
4. Makinson A, Moing VL, Kouanfack C, Laurent C, Delaporte E. Safety of stavudine in the treatment of HIV infection with a special focus on resource-limited settings. Expert Opin Drug Saf 2008; 7:283-293. (Pubitemid 351802828)
5. Joint United Nations Programme on HIV/AIDS. Global report: UNAIDS report on the global AIDS epidemic 2010. (Updated 2011. Accessed 26 December 2011.) Available at http://www.unaids.org/globalreport/documents/20101123-GlobalReport- full-en.pdf
6. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010; 51:496-505.
7. Anderson PL, Rower JE. Zidovudine and lamivudine for HIV infection. Clin Med Rev Ther 2010; 2:a2004.
8. Hill A, Ruxrungtham K, Hanvanich M, et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2007; 8:679-688. (Pubitemid 46547020)
9. Sánchez-Conde M, de Mendoza C, Jimenez-Nacher I, Barreiro P, Gonzalez-Lahoz J, Soriano V. Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity. HIV Clin Trials 2005; 6:197-202. (Pubitemid 41601131)
10. Sungkanuparph S, Techasathit W, Utaipiboon C, et al. Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010. Asian Biomed (Res Rev News) 2010; 4:515-528.
11. Simpson DM, Kitch D, Evans SR, et al. HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology 2006; 66:1679-1687. (Pubitemid 43964622)
12. Kroon ED, Ungsedhapand C, Ruxrungtham K, et al. A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration. AIDS 2000; 14:1349-1356. (Pubitemid 30459507)
13. Moore DM, Harris R, Lima V, et al. Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. J Acquir Immune Defic Syndr 2009; 52:357-363.
14. Moyle G, Sawyer W, Law M, Amin J, Hill A. Changes in hematologic parameters and efficacy of thymidine analoguebased, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies. Clin Ther 2004; 26:92-97. (Pubitemid 38241526)
15. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201. (Pubitemid 38917996)
16. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260. (Pubitemid 43113030)
17. Lichtenstein KA, Delaney KM, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003; 32:48-56. (Pubitemid 36091484)
18. Domingos H, Cunha RV, Paniago AM, Martins DM, Elkhoury EB, Souza AS. Metabolic effects associated to the highly active antiretroviral therapy (HAART) in AIDS patients. Braz J Infect Dis 2009; 13:130-136.
19. Kumar PN, Rodriguez-French A, Thompson MA, et al. A prospective, 96-week study of the impact of trizivir, combivir/nelfinavir, and lamivudine/stavudine/ nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med 2006; 7:85-98.
20. Rey D, Hoen B, Chavanet P, et al. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. J Antimicrob Chemother 2009; 63:380-388.
21. Lapadula G, Costarelli S, Quiros-Roldan E, et al. Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients. Clin Infect Dis 2008; 46:1127-1129. (Pubitemid 351589888)
22. Labarga P, Medrano J, Seclen E, et al. Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients. AIDS 2010; 24:777-779.
23. Smith DE, Chan DJ, Maruszak H, Jeganathan S. Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects. Int J STD AIDS 2011; 22:228-230.